Advice
Following a re-submission.
nebivolol (Nebilet®) is accepted for use within NHS Scotland for the treatment of stable mild and moderate chronic heart failure (CHF) in addition to standard therapies in elderly patients ≥70 years.
Compared to placebo, nebivolol, added to standard therapy, was associated with improved left ventricular function and a reduction in a composite endpoint combining all cause mortality and cardiovascular hospitalisation rates in elderly patients with chronic heart failure. There are no direct comparisons with other beta-blockers that are available at a lower acquisition cost.
Download detailed advice93KB (PDF)
Medicine details
- Medicine name:
- nebivolol tablets 5mg (Nebilet)
- SMC ID:
- 214/05
- Indication:
- chronic heart failure
- Pharmaceutical company
- A Menarini Pharmaceuticals UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 13 August 2007